Effect of Gender on the Response to Hepatitis C Treatment in an Inner-City Population

Abstract Introduction Hepatitis C virus (HCV) is the leading cause of cirrhosis, hepatocellular carcinoma, and liver transplantation in the United States. Response to treatment has improved with the addition of direct acting protease inhibitors. However, there are limited real-world data on the role...

Full description

Saved in:
Bibliographic Details
Published in:Women's health issues 2015-05, Vol.25 (3), p.289-293
Main Authors: Simoes, Priya, MD, Asaad, Adel, MD, Abed, Jean, MD, Engelson, Ellen S., EdD, Kotler, Donald P., MD
Format: Article
Language:English
Subjects:
Adult
Aged
Antiviral Agents - therapeutic use
Cross-Sectional Studies
Female
Genotype
Hepacivirus - drug effects
Hepacivirus - genetics
Hepatitis C - diagnosis
Hepatitis C - drug therapy
Hepatitis C - virology
Humans
Interferon-alpha - therapeutic use
Male
Middle Aged
New York
Obstetrics and Gynecology
Oligopeptides - therapeutic use
Poverty Areas
Residence Characteristics
Ribavirin - therapeutic use
Treatment Outcome
Urban Population
Viral Load - drug effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Introduction Hepatitis C virus (HCV) is the leading cause of cirrhosis, hepatocellular carcinoma, and liver transplantation in the United States. Response to treatment has improved with the addition of direct acting protease inhibitors. However, there are limited real-world data on the role of gender in achieving a sustained virologic response (SVR). Methods We conducted a cross-sectional study in 70 patients treated for HCV, genotype 1 infection with pegylated alpha interferon, ribavirin, and either telaprevir or boceprevir at our inner-city liver clinic. Results The SVR was significantly lower in women than in men (24% vs. 59%; p  
ISSN:1049-3867
1878-4321
DOI:10.1016/j.whi.2015.02.008